Calzaturificio Sicla S.r.l.
Purchase-Price Allocation
Goodwill
$9.0M
2 years of history · ending 2025-03-29 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 19.00% | 19.00% | 19.00% | 19.00% | 25.00% | 25.00% |
| State & Local Income Taxes | -1.90% | 2.02% | 1.30% | 1.50% | -3.90% | -2.20% |
| Foreign Rate Differential | 1.20% | 5.22% | 1.10% | -0.20% | 8.80% | 2.30% |
| Other Adjustments | 1.40% | -33.10% | -0.70% | -1.30% | -2.30% | -2.60% |
| Valuation Allowance Change | -30.90% | 9.56% | -7.30% | -5.80% | 3.10% | -78.80% |
| Tax Law Change | 0.00% | 3.51% | 2.10% | 0.00% | 0.00% | — |
| Effective Tax Rate | -4.70% | 25.91% | 10.10% | 4.50% | 19.00% | -62.20% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $10.0M | $66.0M | $92.0M | $29.0M | −$54.0M | $452.0M |
| Income Taxes Paid (Cash) | — | — | — | — | — | — |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$9.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-03-29
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | +$12M | $24M | — |
| Facility Closing | Facility Closing | +$4M | $5M | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).